CompuGroup: Q4 Hits The Upper End Of The Guidance, M&A Surprises The Market

About: CompuGroup Medical Societas Europaea (CMPVF)
by: After-Market Analytics
This article is exclusive for subscribers.
After-Market Analytics
Long/short equity, value, Growth, research analyst

Strong Q4 growth largely supported by one-off (hardware) revenues and overall solid organic growth.

Profitability falls behind guidance and expectations amid higher R&D investments and hardware sales.

2020 guidance reflects increased level of uncertainty amid continued telematics roll out and adjacent services.

Market celebrated topline beat and acquisition in hospital division with a sharp stock upsurge of 16%.

We see sliding valuation levels in H1 '20 presenting better buying opportunity for long-term (value) investors.

CompuGroup (OTCPK:CMPVF, ETR:COP) has released its preliminary Q4 financial figures on February 5. The results were much stronger than expected with 3 out of 4 segments hitting the upper-end of the guidance. The